+

WO2000027819A3 - Anthranilsäureamide und deren verwendung als arzneimittel - Google Patents

Anthranilsäureamide und deren verwendung als arzneimittel Download PDF

Info

Publication number
WO2000027819A3
WO2000027819A3 PCT/EP1999/008478 EP9908478W WO0027819A3 WO 2000027819 A3 WO2000027819 A3 WO 2000027819A3 EP 9908478 W EP9908478 W EP 9908478W WO 0027819 A3 WO0027819 A3 WO 0027819A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid amides
medicaments
antrhranilic
anthranilic acid
triggered
Prior art date
Application number
PCT/EP1999/008478
Other languages
English (en)
French (fr)
Other versions
WO2000027819A2 (de
Inventor
Andreas Huth
Dieter Seidelmann
Karl-Heinz Thierauch
Guido Bold
Paul William Manley
Pascal Furet
Jeanette Marjorie Wood
Juergen Mestan
Jose Brueggen
Stefano Ferrari
Martin Krueger
Eckhard Ottow
Andreas Menrad
Michael Schirner
Original Assignee
Schering Ag
Novartis Ag
Andreas Huth
Dieter Seidelmann
Thierauch Karl Heinz
Guido Bold
Paul William Manley
Pascal Furet
Jeanette Marjorie Wood
Juergen Mestan
Jose Brueggen
Stefano Ferrari
Martin Krueger
Eckhard Ottow
Andreas Menrad
Michael Schirner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9824579.8A external-priority patent/GB9824579D0/en
Priority claimed from DE1999110396 external-priority patent/DE19910396C2/de
Priority to UA2001063917A priority Critical patent/UA71587C2/uk
Priority to BR9915553-2A priority patent/BR9915553A/pt
Priority to EP99953967A priority patent/EP1129074A2/de
Priority to NZ511413A priority patent/NZ511413A/en
Priority to SK607-2001A priority patent/SK6072001A3/sk
Priority to CA002350208A priority patent/CA2350208A1/en
Priority to AU10454/00A priority patent/AU771180B2/en
Priority to EEP200100258A priority patent/EE200100258A/xx
Application filed by Schering Ag, Novartis Ag, Andreas Huth, Dieter Seidelmann, Thierauch Karl Heinz, Guido Bold, Paul William Manley, Pascal Furet, Jeanette Marjorie Wood, Juergen Mestan, Jose Brueggen, Stefano Ferrari, Martin Krueger, Eckhard Ottow, Andreas Menrad, Michael Schirner filed Critical Schering Ag
Priority to HU0104425A priority patent/HUP0104425A3/hu
Priority to US09/831,506 priority patent/US7122547B1/en
Priority to PL99348349A priority patent/PL348349A1/xx
Priority to JP2000580999A priority patent/JP2002529452A/ja
Priority to EA200100524A priority patent/EA004701B1/ru
Publication of WO2000027819A2 publication Critical patent/WO2000027819A2/de
Publication of WO2000027819A3 publication Critical patent/WO2000027819A3/de
Priority to NO20012245A priority patent/NO320647B1/no
Priority to HK02103628A priority patent/HK1041882A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Es werden Anthranilsäureamide und deren Verwendung als Arzneimittel zur Behandlung von Erkrankungen, die durch persistente Angiogenese ausgelöst werden, sowie deren Zwischenprodukte zur Herstellung der Anthranilsäureamide beschrieben.
PCT/EP1999/008478 1998-11-10 1999-11-09 Anthranilsäureamide und deren verwendung als arzneimittel WO2000027819A2 (de)

Priority Applications (15)

Application Number Priority Date Filing Date Title
UA2001063917A UA71587C2 (uk) 1998-11-10 1999-09-11 Аміди антранілової кислоти та їхнє застосування як лікарських засобів
JP2000580999A JP2002529452A (ja) 1998-11-10 1999-11-09 アントラニル酸アミド及び医薬剤としてのその使用
EA200100524A EA004701B1 (ru) 1998-11-10 1999-11-09 Амиды антраниловой кислоты и их применение в качестве лекарственных средств
US09/831,506 US7122547B1 (en) 1998-11-10 1999-11-09 Anthranilic acid amides and the use thereof as medicaments
NZ511413A NZ511413A (en) 1998-11-10 1999-11-09 Antrhranilic acid amides and the use thereof as medicaments
SK607-2001A SK6072001A3 (en) 1998-11-10 1999-11-09 Anthranilic acid amides and the use thereof as medicaments
CA002350208A CA2350208A1 (en) 1998-11-10 1999-11-09 Antrhranilic acid amides and the use thereof as medicaments
AU10454/00A AU771180B2 (en) 1998-11-10 1999-11-09 Antrhranilic acid amides and the use thereof as medicaments
EEP200100258A EE200100258A (et) 1998-11-10 1999-11-09 Antraniilhappe amiidid ja nende kasutamine ravimitena
BR9915553-2A BR9915553A (pt) 1998-11-10 1999-11-09 Amidas de ácido antranìlico e seu emprego como medicamento
HU0104425A HUP0104425A3 (en) 1998-11-10 1999-11-09 Anthranilic acid amides and the use thereof for the treatment of angiogenesis
EP99953967A EP1129074A2 (de) 1998-11-10 1999-11-09 Anthranilsäureamide und deren verwendung als arzneimittel
PL99348349A PL348349A1 (en) 1998-11-10 1999-11-09 Antrhranilic acid amides and the use thereof as medicaments
NO20012245A NO320647B1 (no) 1998-11-10 2001-05-07 Anthranilsyreamider og anvendelse derav for fremstilling av medikamenter
HK02103628A HK1041882A1 (en) 1998-11-10 2002-05-14 Anthranilic acid amides and their use in manufacturing pharmaceutical agents.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9824579.8A GB9824579D0 (en) 1998-11-10 1998-11-10 Organic compounds
GB9824579.8 1998-11-10
DE1999110396 DE19910396C2 (de) 1999-03-03 1999-03-03 Anthranilsäureamide und deren Verwendung als Arzneimittel
DE19910396.8 1999-03-03

Publications (2)

Publication Number Publication Date
WO2000027819A2 WO2000027819A2 (de) 2000-05-18
WO2000027819A3 true WO2000027819A3 (de) 2000-08-17

Family

ID=26052266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/008478 WO2000027819A2 (de) 1998-11-10 1999-11-09 Anthranilsäureamide und deren verwendung als arzneimittel

Country Status (23)

Country Link
US (1) US7122547B1 (de)
EP (1) EP1129074A2 (de)
JP (1) JP2002529452A (de)
KR (2) KR100855396B1 (de)
CN (1) CN1151133C (de)
AU (1) AU771180B2 (de)
BG (1) BG65371B1 (de)
BR (1) BR9915553A (de)
CA (1) CA2350208A1 (de)
CZ (1) CZ20011631A3 (de)
EA (1) EA004701B1 (de)
EE (1) EE200100258A (de)
HK (1) HK1041882A1 (de)
HR (1) HRP20010402A2 (de)
HU (1) HUP0104425A3 (de)
NO (1) NO320647B1 (de)
NZ (1) NZ511413A (de)
PL (1) PL348349A1 (de)
SK (1) SK6072001A3 (de)
TR (1) TR200101307T2 (de)
UA (1) UA71587C2 (de)
WO (1) WO2000027819A2 (de)
YU (1) YU31801A (de)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002533454A (ja) * 1998-12-23 2002-10-08 イーライ・リリー・アンド・カンパニー 芳香族アミド類
DE10023486C1 (de) * 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
DE10023485A1 (de) * 2000-05-09 2001-11-22 Schering Ag Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel
DE10023484A1 (de) 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
CZ2003182A3 (cs) 2000-06-21 2003-06-18 F. Hoffmann-La Roche Ag Deriváty benzothiazolu
WO2002046172A2 (en) * 2000-12-07 2002-06-13 Cv Therapeutics, Inc. Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20020147198A1 (en) * 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
CN104274442A (zh) 2001-02-19 2015-01-14 诺华股份有限公司 癌症的治疗
US6864255B2 (en) 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
WO2003000678A1 (de) * 2001-05-08 2003-01-03 Schering Aktiengesellschaft Cyanoanthranylamid-derivate und deren verwendung als arzneimittel
CA2453223A1 (en) * 2001-05-08 2002-11-14 Schering Aktiengesellschaft Selective anthranilamide pyridinamides as vegfr-2 and vegfr-3 inhibitors
EP1389201A1 (de) 2001-05-08 2004-02-18 Schering Aktiengesellschaft N-oxidanthranylamid-derivate und deren verwendung als arzneimittel
DE10123587B4 (de) * 2001-05-08 2005-04-07 Schering Ag Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel
DE10123573B4 (de) * 2001-05-08 2005-06-02 Schering Ag N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel
RU2318517C2 (ru) 2001-05-16 2008-03-10 Новартис Аг Комбинация, включающая n-{5-[4-(4-метилпиперазинометил)бензоиламидо]-2-метилфенил}-4-(3-пиридил)-2-пиримидинамин и химиотерапевтический агент
EP1403255A4 (de) * 2001-06-12 2005-04-06 Sumitomo Pharma Rho-kinase-inhibitoren
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US7132438B2 (en) 2001-10-09 2006-11-07 Amgen Inc. Benzimidazole derivatives
GB0126902D0 (en) * 2001-11-08 2002-01-02 Novartis Ag Organic compounds
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
EP1955696B1 (de) 2002-05-16 2014-05-28 Novartis AG Verwendung vom EDG-Rezeptorbindemittel FTY720 bei Krebs
US7307088B2 (en) * 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
US7094789B2 (en) 2002-07-22 2006-08-22 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivatives
US7615565B2 (en) * 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
DE10235690A1 (de) * 2002-07-31 2004-02-19 Schering Ag VEGFR-2 und VEGFR-3 inhibitorische Anthranylamidpyridinamide
EP1388341A1 (de) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Substituierte Acylamino heteroaromatische Verbindungen und ihre Verwendung als Arztneimittel
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
WO2004050610A2 (en) * 2002-12-04 2004-06-17 Gene Logic Inc. Modulators of melanocortin receptor
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
US7696225B2 (en) 2003-01-06 2010-04-13 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-Amino) thiophene compounds
US7087761B2 (en) 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
CA2514940A1 (en) * 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Quinoline-derived amide modulators of vanilloid vr1 receptor
EP1606289B1 (de) * 2003-02-14 2009-12-02 Glaxo Group Limited Carboxamidderivate
ES2527185T3 (es) 2003-03-07 2015-01-21 Santen Pharmaceutical Co., Ltd Nuevos compuestos que tienen un grupo 4-piridilalquiltio como sustituyente
BRPI0410439A (pt) 2003-05-19 2006-06-06 Irm Llc compostos e composições imunossupressoras
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
WO2004108133A2 (en) * 2003-06-05 2004-12-16 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
DE10327719A1 (de) * 2003-06-13 2005-01-20 Schering Ag VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone
US7202260B2 (en) 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
CN1984660B (zh) 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
ES2380201T3 (es) * 2003-07-11 2012-05-09 Merck Patent Gmbh Derivados de benzimidazol
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
KR101179840B1 (ko) 2004-02-17 2012-09-04 산텐 세이야꾸 가부시키가이샤 치환 또는 무치환 아미노기를 도입한 4-피리딜알킬티오기를갖는 신규 고리형 화합물
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
EP1568368A1 (de) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmazeutische Kombination enthaltend einen CDK Inhibitoren und einen VEGF Rezeptor Inhibitoren
WO2005085188A2 (en) * 2004-03-02 2005-09-15 Compass Pharmaceuticals Llc Compounds and methods for anti-tumor therapy
US7427390B2 (en) * 2004-03-10 2008-09-23 Schering Ag Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy
DE102004011720B4 (de) * 2004-03-10 2008-04-03 Bayer Schering Pharma Aktiengesellschaft Radiohalogenierte Benzamidderivate und deren Verwendung in der Tumordiagnostik und Tumortherapie
ES2297710T3 (es) 2004-05-24 2008-05-01 F. Hoffmann-La Roche Ag (4-metoxi-7-morfolin-4-il-benzotiazol-2-il) amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico.
DE102004039876A1 (de) * 2004-06-23 2006-01-26 Lanxess Deutschland Gmbh Herstellung von fluorierten 1,3-Benzodioxanen
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CN101023074B (zh) * 2004-09-22 2012-10-10 詹森药业有限公司 Mdm2及p53间相互作用的抑制剂
EP1655295A1 (de) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamid-Pyridinharnstoffe als VEGF Rezeptor Kinase Inhibitoren
EP1655297A1 (de) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Nicotinamidpyridinharnstoffe als Kinaseinhibitoren des Rezeptors des vaskulären endothelialen Wachstumsfaktors (VEGF)
EP1657241A1 (de) * 2004-11-03 2006-05-17 Schering Aktiengesellschaft Neue Antranilamidpyrdinharnstoffe mit hemmender Wirkung auf VEGF-Rezeptor Kinase
US7906533B2 (en) * 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
DE602005008095D1 (de) 2004-11-05 2008-08-21 Hoffmann La Roche Verfahren zur herstellung von isonikotinsäurederivaten
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1854787B1 (de) 2005-03-03 2010-09-01 Santen Pharmaceutical Co., Ltd. Neue cyclische verbindung mit chinolylalkylthiogruppe
RU2412943C2 (ru) 2005-03-23 2011-02-27 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ АЦЕТИЛЕНИЛ-ПИРАЗОЛО-ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR2
US7906511B2 (en) 2005-03-31 2011-03-15 Santen Pharmaceutical Co., Ltd. Cyclic compound having pyrimidinylalkylthio group
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2623034A1 (en) 2005-09-27 2007-04-05 Novartis Ag Carboxyamine compounds and their use in the treatment of hdac dependent diseases
EP1934214B1 (de) 2005-09-27 2010-04-07 F.Hoffmann-La Roche Ag Oxadiazolylpyrazolopyrimidine als mglur2-antagonisten
US8247556B2 (en) * 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
KR20080071600A (ko) 2005-11-21 2008-08-04 노파르티스 아게 Ｍｔｏｒ 억제제를 사용하는 신경내분비 종양 치료법
CN101312720A (zh) * 2005-11-30 2008-11-26 安斯泰来制药有限公司 2-氨基苯甲酰胺衍生物
CA2644643C (en) 2006-03-22 2015-05-19 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
CA2644649C (en) 2006-03-22 2014-06-17 Janssen Pharmaceutica N.V. Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53
CN102671196B (zh) 2006-04-05 2014-12-03 诺华股份有限公司 用于治疗癌症的治疗剂的组合
EP2026800A1 (de) 2006-05-09 2009-02-25 Novartis AG Kombination aus einem eisenchelatbildner und einem anti-neoplastischen mittel und ihre verwendung
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
DE602007013441D1 (de) 2006-09-29 2011-05-05 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
WO2008077809A1 (en) * 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Process for the manufacture of 7-oxa-bicyclo derivatives
KR101475540B1 (ko) 2007-01-29 2014-12-22 산텐 세이야꾸 가부시키가이샤 혈관 신생 저해 활성을 갖는 신규 옥사디아졸 유도체 및 티아디아졸 유도체
EP2491923A3 (de) 2007-02-15 2012-12-26 Novartis AG Kombinationen therapeutischer Wirkstoffe zur Krebsbehandlung
EP1975166A1 (de) * 2007-03-30 2008-10-01 Bayer Schering Pharma AG Synthese von Anthranilamiden
EP2185541B1 (de) 2007-08-06 2015-01-28 Janssen Pharmaceutica, N.V. Substituierte Phenylendiamine als Inhibitoren der Interaktion zwischen MDM2 und p53
PL2260020T3 (pl) 2008-03-26 2015-01-30 Novartis Ag Hydroksamianowe inhibitory deacetylaz B
JP5553415B2 (ja) 2008-08-27 2014-07-16 レオ ファーマ アクティーゼルスカブ Ｖｅｇｆｒ−２受容体としてのピリジン誘導体、及びタンパク質チロシンキナーゼ阻害剤
US20110223241A1 (en) 2008-10-16 2011-09-15 Celator Pharmaceuticals, Inc. Combination methods and compositions
WO2010071794A1 (en) 2008-12-18 2010-06-24 Novartis Ag New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
ES2478842T3 (es) 2008-12-18 2014-07-23 Novartis Ag Sal clorhidrato del ácido 1-(4-(1-((E)-4-ciclohexil-3-trifluorometil-benziloxiimino)-etil)-2-etil-benzil)-azetidina-3-carboxílico
SI2676953T1 (sl) 2008-12-18 2017-07-31 Novartis Ag Hemifumaratna sol 1-(4-(1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil)-2-etil- benzil)-azetidin-3-karboksilne kisline za uporabo v zdravljenju z limfociti posredovanih bolezni
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
MX2011008195A (es) 2009-02-04 2011-09-06 Janssen Pharmaceutica Nv Derivados de indol como agentes anticancer.
GEP20156250B (en) 2009-06-26 2015-02-25 Novartis Ag 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
KR20120089643A (ko) 2009-08-12 2012-08-13 노파르티스 아게 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
EP2467141B1 (de) 2009-08-17 2018-10-31 Intellikine, LLC Heterocyclische verbindungen und ihre verwendung
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
US20120149661A1 (en) 2009-08-26 2012-06-14 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
AU2010294209A1 (en) 2009-09-10 2012-03-29 Irm Llc Ether derivatives of bicyclic heteroaryls
BR112012010519A2 (pt) 2009-11-04 2017-12-05 Novartis Ag derivados de sulfonamida heterocíclicos
CN102712648A (zh) 2009-11-25 2012-10-03 诺瓦提斯公司 双环杂芳基的与苯稠合的6元含氧杂环衍生物
JP5456908B2 (ja) 2009-12-08 2014-04-02 ノバルティス アーゲー ヘテロ環式スルホンアミド誘導体
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
EP2582681A1 (de) 2010-06-17 2013-04-24 Novartis AG Piperidinylsubstituierte 1,3-dihydro-benzoimidazol-2-ylidenaminderivate
WO2011157787A1 (en) 2010-06-17 2011-12-22 Novartis Ag Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
CA2841142C (en) 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
CN105797158B (zh) 2010-09-10 2019-11-08 Epizyme股份有限公司 人ezh2抑制剂及其应用方法
WO2012035078A1 (en) 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
EP2673277A1 (de) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4] triazolo [4, 3]pyridazinverbindungen als inhibitoren dec-met-tyrosinkinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JP2014507465A (ja) 2011-03-08 2014-03-27 ノバルティス アーゲー フルオロフェニル二環式ヘテロアリール化合物
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
KR20140025492A (ko) 2011-04-28 2014-03-04 노파르티스 아게 17α-히드록실라제/C17,20-리아제 억제제
CA2838029A1 (en) 2011-06-09 2012-12-13 Novartis Ag Heterocyclic sulfonamide derivatives
WO2012175520A1 (en) 2011-06-20 2012-12-27 Novartis Ag Hydroxy substituted isoquinolinone derivatives
WO2012175487A1 (en) 2011-06-20 2012-12-27 Novartis Ag Cyclohexyl isoquinolinone compounds
KR20140077916A (ko) 2011-09-15 2014-06-24 노파르티스 아게 티로신 키나제로서의 6-치환된 3-(퀴놀린-6-일티오)-[1,2,4]트리아졸로[4,3-a]피라딘
CN104080787B (zh) 2011-11-29 2016-09-14 诺华股份有限公司 吡唑并吡咯烷化合物
US9126979B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
KR20140107575A (ko) 2011-12-23 2014-09-04 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
EA201491259A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания
BR112014015339A8 (pt) 2011-12-23 2017-06-13 Novartis Ag compostos para inibição da interação de bcl2 com parceiros de ligação
MX2014007729A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
CN102603729A (zh) * 2012-01-12 2012-07-25 贵州大学 N-(2-(取代苯并噻唑-2-氨基甲酰基)-取代苯基)吡啶甲酰胺类衍生物
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
KR102115047B1 (ko) 2012-04-03 2020-05-26 노파르티스 아게 티로신 키나제 억제제들을 갖는 조합 제품 및 그의 용도
JP6255382B2 (ja) 2012-04-13 2017-12-27 エピザイム，インコーポレイティド ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態
JP6171003B2 (ja) 2012-05-24 2017-07-26 ノバルティス アーゲー ピロロピロリジノン化合物
KR102057365B1 (ko) 2012-10-15 2019-12-18 에피자임, 인코포레이티드 치환된 벤젠 화합물
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
CN103130696B (zh) * 2013-03-21 2014-06-11 山东大学 邻氨基苯甲酰胺类化合物及其制备方法与应用
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
CN103405434A (zh) * 2013-08-22 2013-11-27 中国药科大学 Vegfr-2抑制剂及其用途
SG11201602269QA (en) 2013-10-16 2016-04-28 Epizyme Inc Hydrochloride salt form for ezh2 inhibition
CN104163794A (zh) * 2013-10-17 2014-11-26 中国药科大学 2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
CA3079076A1 (en) 2017-10-18 2019-04-25 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy
WO2019119486A1 (zh) 2017-12-21 2019-06-27 中国科学院合肥物质科学研究院 一类嘧啶类衍生物激酶抑制剂
EP4058465A1 (de) 2019-11-14 2022-09-21 Cohbar Inc. Cxcr4-antagonistenpeptide
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use
US20240216362A1 (en) * 2021-04-19 2024-07-04 Shanghai Yao Yuan Biotechnology Co., Ltd. Benzothiazole and quinoline derivatives for use in treating kawasaki disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409668A (en) * 1964-11-07 1968-11-05 Palazzo Giuseppe Substituted anthranilamides and process for the preparation thereof
JPS50157383A (de) * 1974-05-24 1975-12-19
DE2652144A1 (de) * 1976-11-16 1978-05-18 Merck Patent Gmbh Neue chinazolindione
DE3406416A1 (de) * 1983-02-28 1984-08-30 American Cyanamid Co., Wayne, N.J. N-((omega)-(1h-imidazol-l-yl)-alkyl)-arylamide
EP0564356A1 (de) * 1992-04-01 1993-10-06 Fournier Industrie Et Sante 4-Phenylaminomethylimidazolderivate, Verfahren zu ihrer Herstellung, Angiotensin-II-Rezeptor Antagonisten und ihre therapeutische Verwendung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3226394A (en) * 1964-06-16 1965-12-28 Shulton Inc Pyridylethylated anthranilamides and derivatives thereof
US4568687A (en) * 1983-02-28 1986-02-04 American Cyanamid Company N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical compositions
HUT74450A (en) * 1993-12-27 1996-12-30 Eisai Co Ltd Anthranilic acid derivative and pharmaceutical compns. contg. such compds.
AU716383B2 (en) * 1996-03-15 2000-02-24 Novartis Ag Novel N-7-heterocyclyl pyrrolo(2,3-d)pyrimidines and the use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409668A (en) * 1964-11-07 1968-11-05 Palazzo Giuseppe Substituted anthranilamides and process for the preparation thereof
JPS50157383A (de) * 1974-05-24 1975-12-19
DE2652144A1 (de) * 1976-11-16 1978-05-18 Merck Patent Gmbh Neue chinazolindione
DE3406416A1 (de) * 1983-02-28 1984-08-30 American Cyanamid Co., Wayne, N.J. N-((omega)-(1h-imidazol-l-yl)-alkyl)-arylamide
EP0564356A1 (de) * 1992-04-01 1993-10-06 Fournier Industrie Et Sante 4-Phenylaminomethylimidazolderivate, Verfahren zu ihrer Herstellung, Angiotensin-II-Rezeptor Antagonisten und ihre therapeutische Verwendung

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANN. PHARM. FR. (1989), 46(4), 223-32 *
CHEMICAL ABSTRACTS, vol. 85, no. 3, 19 July 1976, Columbus, Ohio, US; abstract no. 21433p, NODA, KANJI ET AL: "Quinazoline compounds" page 701; XP002135867 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MONTGINOUL, C. ET AL: "Analgesic, anticonvulsant and anti-inflammatory activities of 1H,3H-quinazoline-2,4-diones", XP002135868, retrieved from STN Database accession no. 110:165551h *
HARDTMANN, GOETZ E. ET AL: "Chemistry of 2H-3,1-benzoxazine-2,4(1H)-dione (isatoic anhydrides). 1. Synthesis of N-substituted 2H-3,1-benzoxazine-2,4(1H)-diones", JOURNAL OF HETEROCYCLIC CHEMISTRY., vol. 12, no. 3, 1975, HETEROCORPORATION. PROVO., US, pages 565 - 572, XP002135866, ISSN: 0022-152X *
PASTOR, G. ET AL: "Synthesis of new 1H,3H-quinazoline-2,4-diones", BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE., vol. 5-6, no. 2, 1975, SOCIETE FRANCAISE DE CHIMIE. PARIS., FR, pages 1331 - 1338, XP002135865, ISSN: 0037-8968 *

Also Published As

Publication number Publication date
EE200100258A (et) 2002-12-16
US7122547B1 (en) 2006-10-17
AU1045400A (en) 2000-05-29
NO320647B1 (no) 2006-01-09
HUP0104425A2 (hu) 2002-03-28
PL348349A1 (en) 2002-05-20
KR20010075689A (ko) 2001-08-09
CN1325384A (zh) 2001-12-05
EP1129074A2 (de) 2001-09-05
BG65371B1 (bg) 2008-04-30
KR100777476B1 (ko) 2007-11-16
NO20012245D0 (no) 2001-05-07
WO2000027819A2 (de) 2000-05-18
CA2350208A1 (en) 2000-05-18
TR200101307T2 (tr) 2002-05-21
CZ20011631A3 (cs) 2001-10-17
NO20012245L (no) 2001-07-10
KR100855396B1 (ko) 2008-08-29
YU31801A (sh) 2003-12-31
UA71587C2 (uk) 2004-12-15
HK1041882A1 (en) 2002-07-26
EA004701B1 (ru) 2004-06-24
HRP20010402A2 (en) 2003-10-31
NZ511413A (en) 2004-01-30
EA200100524A1 (ru) 2002-02-28
AU771180B2 (en) 2004-03-18
KR20070087027A (ko) 2007-08-27
BR9915553A (pt) 2001-08-14
CN1151133C (zh) 2004-05-26
HUP0104425A3 (en) 2003-05-28
SK6072001A3 (en) 2002-01-07
JP2002529452A (ja) 2002-09-10
BG105588A (en) 2002-04-30

Similar Documents

Publication Publication Date Title
WO2000027819A3 (de) Anthranilsäureamide und deren verwendung als arzneimittel
WO2001085715A3 (de) Aza- und polyazanthranylamide und deren verwendung als arzneimittel
YU82702A (sh) Ortosupstituisani amidi antranilne kiseline i njihova primena kao sredstva za lečenje
NZ521681A (en) Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis
WO2001045679A3 (de) Verwendung von chemotherapeutika zur topischen behandlung
CA2431565A1 (en) Pharmaceutical compositions based on anticholinergics and ciclesonide
MX9604378A (es) Amidas de acido quinolin-2-carboxilico sustituidas, su preparacion y su empleo como medicamentos, asi como productos intermedios.
TW352384B (en) Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
WO2003032994A3 (de) 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
CA2400268A1 (en) Pyrrolopyrimidinone derivatives, process of preparation and use
WO2000035919A3 (en) Quinoline derivatives
HUP0303296A3 (en) Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours, process for their preparation and pharmaceutical compositions containing them
IL157652A (en) Metalloproteinase inhibitors, compositions comprising them and uses thereof for the preparation of medicaments for treating diseases or conditions mediated by metalloproteinase enzymes
WO2002014311A3 (en) Urea compounds and methods of uses
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
WO2004074232A8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
HUP0301167A3 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
WO1998041513A3 (de) Substituierte aminosalicylsäureamide mit fungizider wirkung und zwischenprodukte zu ihrer herstellung
WO2001051044A3 (en) Substances for use in treating psoriasis
IL141325A0 (en) Tan-1057 derivatives
WO2003024996A3 (de) Antibakterielle makrozyklen
WO2002060382A3 (en) Novel compounds and uses thereof
EP0302303A3 (de) Bizyklische Verbindungen, ihre Verwendung als Pharmazeutika, ihre Herstellung und Zwischenprodukte zu ihrer Herstellung
WO2002070537A3 (en) Fusidic acid derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-318/01

Country of ref document: YU

Ref document number: 99813078.8

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2000 10454

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999953967

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 142618

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/00422/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 511413

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: A 2001 00481

Country of ref document: RO

WWE Wipo information: entry into national phase

Ref document number: 6072001

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2350208

Country of ref document: CA

Ref document number: 2350208

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017005800

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 580999

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2001-1631

Country of ref document: CZ

Ref document number: 10454/00

Country of ref document: AU

Ref document number: 2001/01307

Country of ref document: TR

Ref document number: PA/a/2001/004692

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: P20010402A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 2001/04673

Country of ref document: ZA

Ref document number: 200104673

Country of ref document: ZA

Ref document number: 200100524

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 1999 105588

Country of ref document: BG

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020017005800

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999953967

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09831506

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2001-1631

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 10454/00

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020017005800

Country of ref document: KR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载